245 related articles for article (PubMed ID: 22507918)
1. A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.
Bajsarowicz K; Ahn M; Ackerman L; Dearmond BN; Carlson G; DeArmond SJ
J Neuropathol Exp Neurol; 2012 May; 71(5):449-66. PubMed ID: 22507918
[TBL] [Abstract][Full Text] [Related]
2. A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains.
Spilman P; Lessard P; Sattavat M; Bush C; Tousseyn T; Huang EJ; Giles K; Golde T; Das P; Fauq A; Prusiner SB; Dearmond SJ
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10595-600. PubMed ID: 18647832
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
[TBL] [Abstract][Full Text] [Related]
4. Flow Cytometric Detection of PrP
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046463
[TBL] [Abstract][Full Text] [Related]
5. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
[TBL] [Abstract][Full Text] [Related]
6. Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease.
Jeffrey M; McGovern G; Sisó S; González L
Acta Neuropathol; 2011 Jan; 121(1):113-34. PubMed ID: 20532540
[TBL] [Abstract][Full Text] [Related]
7. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
8. Prion infection of mouse neurospheres.
Giri RK; Young R; Pitstick R; DeArmond SJ; Prusiner SB; Carlson GA
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3875-80. PubMed ID: 16495413
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein.
Homma T; Ishibashi D; Nakagaki T; Satoh K; Sano K; Atarashi R; Nishida N
Sci Rep; 2014 Mar; 4():4504. PubMed ID: 24675871
[TBL] [Abstract][Full Text] [Related]
10. In Situ Temporospatial Characterization of the Glial Response to Prion Infection.
Michael AV; Greenlee JJ; Harm TA; Moore SJ; Zhang M; Lind MS; Greenlee MHW; Smith JD
Vet Pathol; 2020 Jan; 57(1):90-107. PubMed ID: 31331254
[TBL] [Abstract][Full Text] [Related]
11. The neuropathological phenotype in transgenic mice expressing different prion protein constructs.
DeArmond SJ; Yang SL; Cayetano-Canlas J; Groth D; Prusiner SB
Philos Trans R Soc Lond B Biol Sci; 1994 Mar; 343(1306):415-23. PubMed ID: 7913760
[TBL] [Abstract][Full Text] [Related]
12. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
[TBL] [Abstract][Full Text] [Related]
13. Remarkable increases of α1-antichymotrypsin in brain tissues of rodents during prion infection.
Chen C; Xu XF; Zhang RQ; Ma Y; Lv Y; Li JL; Shi Q; Xiao K; Sun J; Yang XD; Shi Q; Dong XP
Prion; 2017 Sep; 11(5):338-351. PubMed ID: 28956708
[TBL] [Abstract][Full Text] [Related]
14. Distinct patterns of spread of prion infection in brains of mice expressing anchorless or anchored forms of prion protein.
Rangel A; Race B; Phillips K; Striebel J; Kurtz N; Chesebro B
Acta Neuropathol Commun; 2014 Jan; 2():8. PubMed ID: 24447368
[TBL] [Abstract][Full Text] [Related]
15. Prions amplify through degradation of the VPS10P sorting receptor sortilin.
Uchiyama K; Tomita M; Yano M; Chida J; Hara H; Das NR; Nykjaer A; Sakaguchi S
PLoS Pathog; 2017 Jun; 13(6):e1006470. PubMed ID: 28665987
[TBL] [Abstract][Full Text] [Related]
16. Enhanced M-CSF/CSF1R Signaling Closely Associates with PrP
Xia Y; Chen C; Chen J; Hu C; Yang W; Wang L; Liu L; Gao LP; Wu YZ; Chen DD; Shi Q; Chen ZB; Dong XP
Mol Neurobiol; 2022 Oct; 59(10):6534-6551. PubMed ID: 35970974
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of infective property of recombinant prion protein amyloids in cultured cells overexpressing cellular prion protein.
Kim DH; Lee HM; Ryou C
J Korean Med Sci; 2014 Dec; 29(12):1604-9. PubMed ID: 25469058
[TBL] [Abstract][Full Text] [Related]
18. Combining autophagy stimulators and cellulose ethers for therapy against prion disease.
Abdulrahman BA; Tahir W; Doh-Ura K; Gilch S; Schatzl HM
Prion; 2019 Jan; 13(1):185-196. PubMed ID: 31578923
[TBL] [Abstract][Full Text] [Related]
19. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.
Bian J; Kang HE; Telling GC
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):6028-33. PubMed ID: 24711410
[TBL] [Abstract][Full Text] [Related]
20. Transgenic models of prion disease.
Scott MR; Supattapone S; Nguyen HO; DeArmond SJ; Prusiner SB
Arch Virol Suppl; 2000; (16):113-24. PubMed ID: 11214913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
